SBC Medical Group Holdings Incorporated

What they do

SBC Medical provides management support across a wide range of healthcare fields to medical institutions, primarily in Japan. Its services include AI-enabled call centers, AI-driven marketing, and AI-assisted site selection for new clinic openings. The company supports a network of affiliated medical corporations, focusing on aesthetic dermatology and non-aesthetic businesses.

Revenue drivers

• Service fees from affiliated clinics — Primary revenue source, derived from management support services (e.g., call centers, marketing) provided to affiliated medical corporations. Fee increases for expanded support are a key growth lever.
• Points business — Revenue from the points program expanded following a change in operating policy, contributing to earnings growth in Q2 2026.
• Multi-brand aesthetic dermatology network — Growth via increasing the number of clinic locations and average fee per clinic (AFPC) across brands like Rize Clinic and Gorilla Clinic.

Recent performance

In Q2 2026, total revenues were $49.2 million, up 13% year-over-year; net income attributable to SBC Medical was $11 million, up 335% year-over-year, with net income margin of 22%. Adjusted EBITDA was $20 million, up 32% year-over-year, with a 41% margin. Basic EPS was $0.10, up 400% year-over-year. As of June 30, 2026, total locations reached 287 (up 34 year-over-year), last-twelve-month visits were 6.9 million (up 10%), and average spend per visit was $287 (up 9%). The company had cash and equivalents of $184.3 million and long-term debt of $37.8 million as of June 30, 2026.

Strategy

Management plans to deepen the multi-brand strategy in aesthetic dermatology domestically and expand the non-aesthetic business as a 'second growth engine.' Internationally, it aims to accelerate growth through a collaboration with OrangeTwist in the U.S. and ASEAN expansion anchored in Thailand. The company is also preparing to enter the Longevity market. Investments focus on AI-enabled platform enhancements to drive growth in locations, AFPC, and service menu breadth. The company intends to deploy its $184 million cash balance for disciplined investment toward the next growth phase.

Risks

• Material weaknesses in internal controls — Disclosure controls and procedures were not effective as of June 30, 2026 due to previously identified material weaknesses, which remained un-remediated.
• Dependence on affiliated medical corporations — Revenue is tied to the success and cooperation of affiliated clinics; fee increases may strain relationships, though management emphasizes a 'win-win' approach.
• Concentration in Japan — Operations are primarily in Japan, exposing the company to regional economic, regulatory, and healthcare market risks.
• Emerging growth company and smaller reporting company status — Exemptions from certain reporting requirements may reduce transparency, and the company's status could change, affecting obligations.

Outlook

Management believes Q2 2026 marks a clear reacceleration, with growth fundamentals strengthening. Expected fee revisions for five affiliated medical corporations and expanded support for Rize and Gorilla clinics could increase service fees by approximately $15 million annually (at 158.1 yen/USD), if fully realized for a year. The company is pursuing multiple growth engines, including AI-enabled services, international expansion, and entry into new markets like Longevity.